Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.68 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | PI4KA | P42356 | 2/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.56 |
| ▸ | AHCY | P23526 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608687 | 1.00 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| Water SCHEMBL28104561 | 0.99 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| Water SCHEMBL28104578 | 0.99 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15045890 | 0.88 | CYP3A4 (0.70) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15257613 | 0.86 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL19831528 | 0.86 | ADORA2A (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL10015788 | 0.85 | ADORA2A (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL1249908 | 0.85 | ADORA2A (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15161690 | 0.84 | CYP3A4 (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28664282 | 0.84 | CYP3A4 (0.65) | CYP3A4ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106046055-A | R-9-(2-phosphonomethoxy propyl)-adenine monohydrate crystals, preparation thereof and preparation of tenofovir disoproxil fumarate | 湖北丽益医药科技有限公司 | 2016-10-26 | — | — | CN | claimed |
| US-20230404976-A1 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND NUCLEOSIDE ANALOG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-12-21 | — | — | US | disclosed |
| EP-3386512-B1 | ANTIVIRAL PHOSPHODIAMIDE PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4241770-A1 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND NUCLEOSIDE ANALOG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-110452269-A | A method of tenofovir is prepared using microreactor | QILU ANTIBIOTICS LINYI PHARMACEUTICAL CO LTD | 2019-11-15 | — | — | CN | disclosed |
| EP-2998307-B1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | BEIJING SL PHARMACEUTICAL CO LTD (CN) | 2018-10-31 | — | — | EP | disclosed |
| CN-106046055-A | R-9-(2-phosphonomethoxy propyl)-adenine monohydrate crystals, preparation thereof and preparation of tenofovir disoproxil fumarate | 湖北丽益医药科技有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-20160115186-A1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2016-04-28 | — | — | US | disclosed |
| EP-2998307-A1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | Beijing Meibeita Drug Res Co., Ltd (CN) | 2016-03-23 | — | — | EP | disclosed |
| US-8884011-B2 | Nucleotide analogues as precursor molecules for antivirals | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2014-11-11 | — | — | US | disclosed |
| US-8884011-B2 | Nucleotide analogues as precursor molecules for antivirals | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2014-11-11 | — | — | US | disclosed |
| US-8884011-B2 | Nucleotide analogues as precursor molecules for antivirals | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2014-11-11 | — | — | US | disclosed |
| US-20100099869-A1 | NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2010-04-22 | — | — | US | disclosed |
| US-20100099869-A1 | NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2010-04-22 | — | — | US | disclosed |
| US-20100099869-A1 | NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS (FR) | 2010-04-22 | — | — | US | disclosed |
| WO-2008056264-A2 | NOVEL NUCLEOTIDE ANALOGUES AS PERCURSOR MOLECULES FOR ANTIVIRALS | CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230404976-A1 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND NUCLEOSIDE ANALOG | HAVCR2, PNP, SLC10A1 | CYP3A4 955/4885ADORA2A 2514/4885ADORA1 2780/4885 |
| US-20160115186-A1 | PHOSPHORIC ACID/PHOSPHONIC ACID DERIVATIVES AND MEDICINAL USES THEREOF | P2RY1, SQLE, PHOSPHO1 | CYP3A4 792/4885ADORA2A 151/4885ADORA1 62/4885 |
| US-20100099869-A1 | NOVEL NUCLEOTIDE ANALOGUES AS PRECUSOR MOLECULES FOR ANTIVIRALS | NUDT1, P2RY1, HPRT1 | CYP3A4 1622/4885ADORA2A 79/4885ADORA1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.